Controlled in vivo trials are an important means of confirming the validity and application of laboratory testing. Randomized controlled clinical trials with additional toxicity measurements have confirmed these effects.
Research by Klukowska and colleagues incorporated subgingival plaque sampling in sites up to 4 mm in depth in a 4-week randomized controlled clinical trial of twice daily unsupervised brushing with a 0.454% bioavailable SnF2 dentifrice, wherein both a low gingival bleeding cohort (‘healthy’) and a high bleeding cohort (‘diseased’) were evaluated.35 Clinical effectiveness trials of marketed dentifrices do not commonly include subgingival plaque sampling, but its inclusion in this trial provided insight into the depths of penetration of SnF2, its retention, and its ability to reduce subgingival plaque toxicity. At Week 4, both cohorts saw significant (42% to 53%) mean reductions in gingival bleeding. The plaque sampling results in both the healthy and diseased groups provided evidence following use of SnF2 of notably decreased LPS/LTA dye activity and TLR activity. Morning wake-up plaque samples via salivary lavage showed significantly suppressed short-chain carboxylic acid toxins for both the low and high bleeding groups as well, suggesting robust substantivity.35,36
The researchers noted the important implication of this research and a previous complementary trial:37 The effects of SnF2 to bind with endotoxins and thereby limit TRL4/TRL2 in initiating the inflammatory cascade manifested both in the diseased, high bleeding sites and also in the low bleeding sites with minimal measurable disease, suggesting a preventive as well as a treatment gingivitis strategy.
A subsequent clinical trial evaluating SnF2 penetration within the sulcus and retention in gingival crevicular fluid (GCF) provided further evidence that SnF2 can influence the pathogenicity of microflora subgingivally.38 In this 2-week trial of subjects with a minimum of twenty bleeding dental pockets up to 4mm in depth and no recent SnF2 exposure, GCF samples were analyzed by mass spectrometry for the presence of tin (a stannous fluoride marker) at both 30 minutes and 12 hours after brushing with a bioavailable SnF2 dentifrice on Day 1. The results showed that significant (P<0.0001) levels of tin compared with baseline were detected in the GCF samples. Higher tin levels were seen at Day 14 after 2 weeks of home dentifrice use, suggesting an incremental effect with ongoing use.
More confirmation of bioavailable SnF2’s ability to diminish the virulence of subgingival plaque – and thus the development of gingivitis – was demonstrated by recent clinical research evaluating gingival inflammation and bleeding in 99 adult subjects with gingivitis.39 After 8 weeks of at-home 0.454% SnF2 dentifrice use, significant reductions in gingivitis and bleeding versus baseline were observed. These clinical observations were consistent with the results of subgingival plaque sampling, where TLR2 assay analyses of hTLR2 reporter gene activity showed significant (P=0.0004) mean reductions following two months of SnF2 brushing (Figure 9).
Incorporating SnF2 in a dentifrice to yield maximum aesthetics and efficacy – including full bioavailability – mandates precise, well-skilled formulation.40,41 In recent years, several technological advances resulting from ongoing scientific innovations and testing have led to bioavailable SnF2 formulations which have provided superior tartar control and whitening benefits, along with the therapeutic benefits, versus a variety of dentifrice controls in multiple clinical trials. The extensive clinical research program by Procter & Gamble on SnF2 dentifrice, which has spanned numerous decades, resulted in a Crest dentifrice being the first to be recognized for seven attributes applicable to toothpastes in the American Dental Association Seal of Acceptance program: